Summary & Overview
HCPCS J3316: Triptorelin Extended-Release Injection, 3.75 mg
HCPCS Level II code J3316 identifies the extended-release injectable formulation of triptorelin, 3.75 mg. Triptorelin is a GnRH agonist used for medical suppression of gonadal steroid production in a range of clinical indications; the HCPCS designation signals billing for the drug as a separately payable J‑code. Nationally, accurate use of J3316 affects drug utilization reporting, payer coverage determinations, and facility billing workflows for outpatient injectable therapies.
This analysis covers common national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how the code is used clinically and administratively, typical sites of service, and which payers are included in the coverage review. The publication also summarizes available benchmarks and policy considerations relevant to outpatient administration of depot GnRH agonists and highlights any recent policy updates or common billing considerations where applicable.
The report is intended to inform revenue cycle teams, clinicians who administer depot injections, and policy analysts about code purpose, payer coverage landscape, and areas to monitor for reimbursement or policy change. Data not available in the input will be noted where appropriate.
Billing Code Overview
HCPCS Level II code J3316 represents an injection of triptorelin, extended-release, 3.75 mg. This medication is a gonadotropin-releasing hormone (GnRH) agonist formulated for sustained release and is typically used for conditions requiring medical suppression of sex hormone production.
-
Service type: Injectable medication administered as an intramuscular or subcutaneous depot injection
-
Typical site of service: Outpatient clinic, physician office, or ambulatory infusion/medication administration setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult female presenting to an outpatient ambulatory clinic or specialty reproductive endocrinology, urology, or oncology clinic for intramuscular therapy with a gonadotropin-releasing hormone (GnRH) agonist. The medication J3316 (triptorelin, extended-release, 3.75 mg) is administered to achieve temporary medical castration or ovarian suppression. Common indications include hormone-sensitive prostate cancer in men, endometriosis or uterine fibroid-related symptoms in women, and assisted reproduction protocols requiring pituitary suppression.
The clinical workflow includes: initial evaluation and documentation of indication and informed consent; review of allergies and contraindications; verification of the medication order and dose; preparation of the extended-release depot formulation; administration via intramuscular injection (typically gluteal or deltoid) by a licensed nurse or physician; observation for immediate adverse reaction (15–30 minutes in office); and documentation of lot number, expiration date, route, site, and any patient response. Follow-up scheduling for repeat monthly injections and monitoring of clinical response, hormone levels, and adverse effects is arranged.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no modifier applies; standard billing for the service |